Medscape1d
Despite Price Caps, Some Still Struggle to Access Insulin
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Minnesota Daily10d
Insulin costs capped at $35 per month in Minnesota
Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...
pharmaphorum4d
Civica plans shake-up of insulin sector with low-cost biosimilars
The average wholesale prices of the originator insulin are around $329 per vial and $510 for five pens, according to Civica, which says it will start clinical trials of the biosimilars this year ...
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
Pasadena Star-News17dOpinion
Insulin prices are falling due to market forces — no price caps required
If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...
BioSpace3d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...
Monthly Prescribing Reference2d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.